

Loss of CEACAM1 is associated with poor prognosis and peritoneal dissemination of patients with gastric cancer

Akihiro Takeuchi, MD¹, Shozo Yokoyama, MD, PhD^{1*}, Mikihiro Nakamori, MD, PhD¹, Masaki Nakamura, MD, PhD¹, Toshiyasu Ojima, MD, PhD¹, Shunsuke Yamaguchi, MD, PhD¹, Yasuyuki Mitani, MD¹, John E. Shively, PhD², and Hiroki Yamaue, MD, PhD¹

¹ Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, 641-0045, Japan

² Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, CA, 91010 USA

Figure 5A

NUGC3



Figure 5A

MKN7

